Found 19 Cardiomyopathy trials
A listing of Cardiomyopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM) AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
PURPOSE/DESCRIPTION: This is an open label trial to collect long-term safety and tolerability data, including assessments of cardiac structure and function, during chronic dosing with CK3773274. A cardiac magnetic resonance (CMR) imaging sub-study will assess the effects of long-term dosing on cardiac morphology, function and fibrosis.
A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …
Study to Evaluate Safety and Efficacy of Ck3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
The purpose of this study is to compare the effects of CK-3773274, and placebo, on the exercise and health status of patients with oHCM. The safety and tolerability of CK-3773274 will also be studied.
A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Please see section 1 of the full protocol
Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
Magnetic Resonance Imaging Based Risk Stratification for Defibrillator Implantation in Heart Failure Patients Requiring Cardiac Resynchronisation Therapy-published version (MADURAI CRT)
This randomized study aimed to compare the efficacy of LBBP without defibrillator vs biventricular pacing with defibrillator (BiV-ICD/CRT-D) in patients with LB-NICM and left ventricular ejection fraction (LVEF) ≤35% risk categorized by CMR imaging.
INFINITY-Prospective Cohort Study of Mechanistic Associations between Intra-Myocardial Fat Deposition and Ventricular Tachycardia in Ischemic Cardiomyopathy
This study will focus on fat buildup inside the heart muscle, a newly recognized factor that makes patients vulnerable to such fast heart rates, or ventricular tachycardia, after a heart attack. This work may identify more successful strategies for curing dangerously fast heart rates. Adult subjects with prior history of …
Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
This is a multicenter study to evaluate the long-term safety and tolerability of mavacamten in participants with nHCM who completed MAVERICK-HCM through Week 24 and enroll into this study within 3 months. All participants will receive active study drug as described below, but their status (active or placebo) in the …
11 - 19 of 19
- 1
- 2
Please choose between Voice or SMS based delivery of verification code
or